Talphera (NASDAQ:TLPH) Stock Price Down 0.3% – Here’s What Happened

Talphera, Inc. (NASDAQ:TLPH) shares traded down 0.3% on Thursday . The company traded as low as $0.7808 and last traded at $0.8079. 39,878 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 173,561 shares. The stock had previously closed at $0.81.

Analysts Set New Price Targets

Several brokerages have weighed in on TLPH. Wall Street Zen upgraded Talphera to a “hold” rating in a research note on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Talphera in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Talphera presently has an average rating of “Hold” and an average price target of $6.00.

Talphera Stock Performance

The firm has a 50 day moving average price of $1.00 and a two-hundred day moving average price of $0.99. The company has a market cap of $36.20 million, a P/E ratio of -2.04 and a beta of 0.46.

Insider Buying and Selling

In other news, insider Shakil Aslam acquired 35,000 shares of Talphera stock in a transaction that occurred on Thursday, February 12th. The stock was bought at an average price of $0.81 per share, with a total value of $28,350.00. Following the completion of the purchase, the insider owned 83,178 shares in the company, valued at approximately $67,374.18. The trade was a 72.65% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Vincent J. Angotti acquired 105,364 shares of the stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average price of $0.81 per share, for a total transaction of $85,344.84. Following the transaction, the chief executive officer directly owned 586,954 shares of the company’s stock, valued at $475,432.74. This represents a 21.88% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought 220,364 shares of company stock valued at $178,495 over the last three months. Insiders own 5.70% of the company’s stock.

Institutional Trading of Talphera

Several hedge funds and other institutional investors have recently bought and sold shares of TLPH. Cantor Fitzgerald L. P. bought a new stake in shares of Talphera in the fourth quarter worth about $658,000. Diadema Partners LP bought a new position in shares of Talphera during the fourth quarter valued at approximately $156,000. Persistent Asset Partners Ltd purchased a new stake in Talphera in the fourth quarter worth $42,000. Mariner LLC lifted its stake in Talphera by 132.0% in the fourth quarter. Mariner LLC now owns 58,000 shares of the company’s stock worth $66,000 after acquiring an additional 33,000 shares during the period. Finally, Renaissance Technologies LLC increased its position in Talphera by 412.6% during the 4th quarter. Renaissance Technologies LLC now owns 257,380 shares of the company’s stock valued at $293,000 after purchasing an additional 207,166 shares during the period. Institutional investors own 37.67% of the company’s stock.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe.